Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2017

9 - 12 Dec 2017
Georgia World Congress Center, Atlanta, United States of America
Next generation sequencing identifies smoldering multiple myeloma patients with ...
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )
14 Dec 2017
Venetoclax plus rituximab for patients with relapsed / refractory CLL
Prof John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
Venetoclax plus rituximab for patients with relapsed / refractory CLL ( Prof John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
12 Dec 2017
Daratumumab for patients with multiple myeloma
Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain
Daratumumab for patients with multiple myeloma ( Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain )
12 Dec 2017
Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melpha...
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athen...
Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone for multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
12 Dec 2017
ASH 2017: Immunotherapy for multiple myeloma
Prof Paul Richardson & Dr Wenming Chen
ASH 2017: Immunotherapy for multiple myeloma ( Prof Paul Richardson &  Dr Wenming Chen )
12 Dec 2017
Multiple myeloma highlights from ASH 2017
Prof Meral Beksac - Ankara University Medical School, Ankara, Turkey
Multiple myeloma highlights from ASH 2017 ( Prof Meral Beksac - Ankara University Medical School, Ankara, Turkey )
12 Dec 2017
Multiple myeloma analysis from ASH 2017
Dr Maxim Solovev and Dr Sung-Soo Yoon
Multiple myeloma analysis from ASH 2017 ( Dr Maxim Solovev and Dr Sung-Soo Yoon )
12 Dec 2017
Edoxaban versus dalteparin for venous thromboembolism associated with cancer
Dr Harry Büller - University of Amsterdam, Amsterdam, Netherlands
Edoxaban versus dalteparin for venous thromboembolism associated with cancer ( Dr Harry Büller - University of Amsterdam, Amsterdam, Netherlands )
12 Dec 2017
Lenalidomide with rituximab for mantle cell lymphoma
Prof Jia Ruan - Weill Cornell Medicine and New York Presbyterian Hospital, New Y...
Lenalidomide with rituximab for mantle cell lymphoma ( Prof Jia Ruan - Weill Cornell Medicine and New York Presbyterian Hospital, New York, USA )
11 Dec 2017
Combination chemotherapy for multiple myeloma
Dr Muzaffar Qazilbash - MD Anderson Cancer Center, Houston, USA
Combination chemotherapy for multiple myeloma ( Dr Muzaffar Qazilbash - MD Anderson Cancer Center, Houston, USA )
11 Dec 2017
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethaso...
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athen...
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
11 Dec 2017
Gilteritinib combination with induction and consolidation chemo in newly diagnos...
Dr Keith Pratz - Johns Hopkins University, Baltimore, USA
Gilteritinib combination with induction and consolidation chemo in newly diagnosed AML ( Dr Keith Pratz - Johns Hopkins University, Baltimore, USA )
11 Dec 2017
REGN2810 alone or in combination with REGN1979 for B-lymphoid malignancies
Dr Max Topp - University of Wurzburg, Wurzburg, Germany
REGN2810 alone or in combination with REGN1979 for B-lymphoid malignancies ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
11 Dec 2017
Results of the AML 12 trial
Dr Ana Garrido - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Results of the AML 12 trial ( Dr Ana Garrido - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )
11 Dec 2017
Added ibrutinib in first-line CLL treatment
Dr Nitin Jain - MD Anderson Cancer Center, Houston, USA
Added ibrutinib in first-line CLL treatment ( Dr Nitin Jain - MD Anderson Cancer Center, Houston, USA )
11 Dec 2017
T cell therapy for ALL
Dr Max Topp - University of Wurzburg, Wurzburg, Germany
T cell therapy for ALL ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
11 Dec 2017
Immunosuppressive therapy in myelodysplastic syndrome
Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA
Immunosuppressive therapy in myelodysplastic syndrome ( Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA )
11 Dec 2017
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma
Dr Michael Wang - MD Anderson Cancer Center, Houston, USA
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )
11 Dec 2017
Hypomethylating agents for relapsed and refractory acute myeloid leukaemia
Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA
Hypomethylating agents for relapsed and refractory acute myeloid leukaemia ( Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA )
11 Dec 2017
Epidemiology data for acute myeloid leukaemia and the ALESE study
Dr James Foran - Mayo Clinic Florida, Jacksonville, USA
Epidemiology data for acute myeloid leukaemia and the ALESE study ( Dr James Foran - Mayo Clinic Florida, Jacksonville, USA )
10 Dec 2017
Combination of steroids with ponatinib as frontline therapy for acute lymphoblas...
Dr Giovanni Martinelli - University of Bologna, Bologna, Italy
Combination of steroids with ponatinib as frontline therapy for acute lymphoblastic leukaemia ( Dr Giovanni Martinelli - University of Bologna, Bologna, Italy )
10 Dec 2017
Shortening the time to manufacture CAR T-cells
Dr Partow Kebriaei - MD Anderson Center, Houston, USA
Shortening the time to manufacture CAR T-cells ( Dr Partow Kebriaei - MD Anderson Center, Houston, USA )
10 Dec 2017
ASPIRE update: Carfilzomib triplet for relapsed / refractory myeloma
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
ASPIRE update: Carfilzomib triplet for relapsed / refractory myeloma ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
10 Dec 2017
Early platelet drop in myelodysplastic syndrome highlights prognostic classifier
Dr Raphael Itzykson - Hopital Saint-Louis, Paris Diderot University, Paris, Fran...
Early platelet drop in myelodysplastic syndrome highlights prognostic classifier ( Dr Raphael Itzykson - Hopital Saint-Louis, Paris Diderot University, Paris, France )
10 Dec 2017
Six-month follow up of CTL019 for diffuse large B-cell lymphoma
Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Six-month follow up of CTL019 for diffuse large B-cell lymphoma ( Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
10 Dec 2017
New treatment strategies for multiple myeloma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
New treatment strategies for multiple myeloma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
10 Dec 2017
Anti-BCMA CAR T cell therapy for multiple myeloma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Anti-BCMA CAR T cell therapy for multiple myeloma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
10 Dec 2017
Axicabtagene ciloleucel for patients with non-hodgkin lymphoma
Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
Axicabtagene ciloleucel for patients with non-hodgkin lymphoma ( Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )
10 Dec 2017
Data from the CLARITY trial of ibrutinib plus venetoclax
Prof Peter Hillmen - University of Leeds, Leeds, UK
Data from the CLARITY trial of ibrutinib plus venetoclax ( Prof Peter Hillmen - University of Leeds, Leeds, UK )
10 Dec 2017
Mogamulizumab for cutaneous T- cell lymphoma
Prof Youn Kim - Stanford University, Stanford, CA
Mogamulizumab for cutaneous T- cell lymphoma ( Prof Youn Kim - Stanford University, Stanford, CA )
10 Dec 2017
Phase 1 study of Blu-285 in advanced systemic mastocytosis
Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA
Phase 1 study of Blu-285 in advanced systemic mastocytosis ( Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA )
10 Dec 2017
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial
Prof Peter Hillmen - University of Leeds, Leeds, UK
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial ( Prof Peter Hillmen - University of Leeds, Leeds, UK )
10 Dec 2017
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-...
Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma ( Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
10 Dec 2017
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study ( Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada )
10 Dec 2017
New treatments for acute myeloid leukaemia
Dr Anna Halpern - Seattle Cancer Care Alliance, Seattle, USA
New treatments for acute myeloid leukaemia ( Dr Anna Halpern - Seattle Cancer Care Alliance, Seattle, USA )
10 Dec 2017
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lympho...
Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma ( Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada )
10 Dec 2017
Long term follow up on the ZUMA-1 trial for nHL
Dr Sattva Neelapu - MD Anderson Center, Houston, USA
Long term follow up on the ZUMA-1 trial for nHL ( Dr Sattva Neelapu - MD Anderson Center, Houston, USA )
10 Dec 2017
BLU-285 for advanced systemic mastocytosis
Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA
BLU-285 for advanced systemic mastocytosis ( Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA )
10 Dec 2017
Mogamulizumab demonstrates significant improvement in progression free survival ...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
Mogamulizumab demonstrates significant improvement in progression free survival for CTCL ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Dec 2017
Autoimmune and infectious diseases among diffuse large B-cell lymphoma survivors
Dr Tanaya Shree - Stanford University Medical Center, Stanford, USA
Autoimmune and infectious diseases among diffuse large B-cell lymphoma survivors ( Dr Tanaya Shree - Stanford University Medical Center, Stanford, USA )
9 Dec 2017
Autologous haematopoietic cell transplant for mantle cell lymphoma
Dr Stefan Barta - Fox Chase Cancer Center, Philadelphia, USA
Autologous haematopoietic cell transplant for mantle cell lymphoma ( Dr Stefan Barta - Fox Chase Cancer Center, Philadelphia, USA )
9 Dec 2017
Dexamethasone and the UKALL 2011 trial
Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK
Dexamethasone and the UKALL 2011 trial ( Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )
9 Dec 2017